Search

Samir D Undevia

from Burr Ridge, IL
Age ~54
Get Report
Also known as:
Dinesh Undevia, Dinesh Etal Undevia, Samir A, Devia U Samir
Related to:
Indra S Kumar, 75Ashok Kumar, 79S KumarSharad Kumar, 49Ramana V Yedavalli, 49Neela D Undevia, 81Dinesh V Undevia, 84Nina D Undevia, 51Nidhi S Undevia, 52
Connected to:
Michael Undi, 65Peter Undiandeye, 38Alfonso Undiano, 33Joi L Undiano, 77Anne E Undis, 35Andrea M Undlin, 39Brian G Undlin, 31Kimberly A Undorf, 48Michael A Undorf, 49Adam J Undorfer, 38

Samir Undevia Phones & Addresses

  • Burr Ridge, IL
  • 1416 Talbot Dr, Naperville, IL 60565 (630) 416-7441
  • 5050 Lake Shore Dr, Chicago, IL 60615 (773) 493-3648
  • 3451 Hoyne Ave, Chicago, IL 60618 (773) 404-5885
  • 211 Ohio St, Chicago, IL 60611
  • 233 Wacker Dr, Chicago, IL 60606
  • New York, NY
  • 1111 S Laflin St APT 713, Chicago, IL 60607 (312) 259-5653

Work

Company: Edward Hospital Oncology Address: 801 S Washington St Suite 111, Naperville, IL 60540

Education

School / High School: New York University School Of Medicine 1997

Images

Professional Records

Medicine Doctors

Samir Undevia Photo 1

Dr. Samir D Undevia - MD (Doctor of Medicine)

View page
Hospitals:
120 Spalding Dr Suite 111, Naperville, IL 60540

901 W Wellington Ave, Chicago, IL 60657

Edward Hospital Oncology
801 S Washington St Suite 111, Naperville, IL 60540

Plainfield Cancer Center
24600 W 127Th St, Plainfield, IL 60585

Edward Hospital & Health Services
801 South Washington, Naperville, IL 60540

Loyola University Medical Center
2160 South 1St Avenue, Maywood, IL 60153
Education:
Medical Schools
New York University School Of Medicine
Graduated: 1997
Samir Undevia Photo 2

Samir D. Undevia

View page
Specialties:
Hematology/Oncology
Work:
Edward Cancer Center
120 Spalding Dr STE 111, Naperville, IL 60540
(630) 527-3788 (phone), (630) 646-6071 (fax)

Edward Cancer Center
24600 W 127 St, Plainfield, IL 60585
(815) 731-3401 (phone), (630) 646-6071 (fax)

University Of Chicago Medical Center Hematology Oncology
5758 S Maryland Ave STE 6C6D, Chicago, IL 60637
(773) 702-6149 (phone), (773) 834-7072 (fax)
Education:
Medical School
New York University School of Medicine
Graduated: 1997
Procedures:
Bone Marrow Biopsy
Chemotherapy
Conditions:
Iron Deficiency Anemia
Non-Hodgkin's Lymphoma
Acute Bronchitis
Anemia
Atrial Fibrillation and Atrial Flutter
Languages:
English
Russian
Spanish
Tagalog
Description:
Dr. Undevia graduated from the New York University School of Medicine in 1997. He works in Chicago, IL and 2 other locations and specializes in Hematology/Oncology. Dr. Undevia is affiliated with Edward Hospital and Northwestern Memorial Hospital.

Business Records

Name / Title
Company / Classification
Phones & Addresses
Samir D. Undevia
Hematology
Edward Hospital
Osteopathic Physician's Office Medical Doctor's Office
24600 W 127 St, Plainfield, IL 60585
Samir Dinesh Undevia
Samir Undevia MD
Internist
901 W Wellington Ave, Chicago, IL 60657
(773) 296-7089
Samir D. Undevia
Hematology
Edward Plainfield Outpatient Center
General Hospital
24600 W 127 St, Plainfield, IL 60585
Samir D. Undevia
Oncology
Edward Cancer Center
Medical Doctor's Office · Hematologists · Oncology · Radiology · Family Doctor · Internist
120 Spalding Dr, Naperville, IL 60540
(630) 527-3788, (630) 527-3790

Publications

Us Patents

Methods And Compositions Relating To Pharmacogenetics Of Different Gene Variants In The Context Of Irinotecan-Based Therapies

View page
US Patent:
20090247475, Oct 1, 2009
Filed:
May 12, 2006
Appl. No.:
11/913150
Inventors:
Mark J. Ratain - Chicago IL, US
Federico Innocenti - Chicago IL, US
Deanna L. Kroetz - Burlingame CA, US
Samir Undevia - Naperville IL, US
Tan D. Nguyen - Laguna Beach CA, US
Wanqing Liu - Chicago IL, US
Assignee:
The Regents of the University of California - Oakland CA
The University of Chicago - Chicago IL
International Classification:
C12Q 1/68
A61K 31/4545
US Classification:
514 23, 435 6, 514283
Abstract:
The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.

Methods And Compositions Relating To The Pharmacogenetics Of Different Gene Variants

View page
US Patent:
20090017452, Jan 15, 2009
Filed:
Mar 7, 2005
Appl. No.:
10/591484
Inventors:
Mark J. Ratain - Chicago IL, US
Federico Innoceti - Chicago IL, US
Deanna L. Kroetz - Burlingame CA, US
Samir Undevia - Naperville IL, US
Tan D. Nguyen - San Francisco CA, US
Wanqing Liu - Chicago IL, US
Assignee:
UNIVERSITY OF CHICAGO - Chicago IL
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.
Control profile
Samir D Undevia from Burr Ridge, IL, age ~54 Get Report